King's College London

Research portal

Differential medication overuse risk of novel anti-migraine therapeutics

Research output: Contribution to journalArticle

Standard

Differential medication overuse risk of novel anti-migraine therapeutics. / Saengjaroentham, Chonlawan; Strother, Lauren; Sultan-Jabir, Mohammad; Dripps, Isaac; Pradhan, Amynah; Goadsby, Peter; Holland, Philip.

In: Brain, 03.05.2020.

Research output: Contribution to journalArticle

Harvard

Saengjaroentham, C, Strother, L, Sultan-Jabir, M, Dripps, I, Pradhan, A, Goadsby, P & Holland, P 2020, 'Differential medication overuse risk of novel anti-migraine therapeutics', Brain.

APA

Saengjaroentham, C., Strother, L., Sultan-Jabir, M., Dripps, I., Pradhan, A., Goadsby, P., & Holland, P. (Accepted/In press). Differential medication overuse risk of novel anti-migraine therapeutics. Brain.

Vancouver

Saengjaroentham C, Strother L, Sultan-Jabir M, Dripps I, Pradhan A, Goadsby P et al. Differential medication overuse risk of novel anti-migraine therapeutics. Brain. 2020 May 3.

Author

Saengjaroentham, Chonlawan ; Strother, Lauren ; Sultan-Jabir, Mohammad ; Dripps, Isaac ; Pradhan, Amynah ; Goadsby, Peter ; Holland, Philip. / Differential medication overuse risk of novel anti-migraine therapeutics. In: Brain. 2020.

Bibtex Download

@article{460b633d9b424db688aee9fb2417d9da,
title = "Differential medication overuse risk of novel anti-migraine therapeutics",
abstract = "Medication overuse headache is estimated to affect two percent of the population, and is ranked in the top 20 most disabling disorders, due to its high level of disability. Several therapies used in the treatment of acute migraine are thought to be associated with medication overuse headache, including opioids and triptans. With limited treatment options, it is critical to determine the risk profile of novel therapies prior to their widespread use. The current study explores the potential medication overuse risk of two novel therapeutic drug classes, namely the ditans: 5-HT1F receptor agonists, and the gepants: calcitonin gene-related peptide receptor antagonists, in a preclinical model of medication overuse. Persistent exposure of mice to the 5-HT1F agonist LY344864, but not olcegepant produced a significant reduction in hindpaw and orofacial mechanical withdrawal thresholds as a surrogate readout of allodynia. In agreement, only LY344864 induced neuroplastic changes in trigeminal sensory afferents, increasing calcitonin gene-related peptide expression and basal trigeminal nociception. Our data highlight a differential medication overuse headache risk profile for the ditan and gepant classes of drugs that has important implications for their clinical use and patient education to help reduce the burden of medication overuse headache.",
keywords = "Migraine, Headache, Trigeminal ganglion, Trigeminal Nerve",
author = "Chonlawan Saengjaroentham and Lauren Strother and Mohammad Sultan-Jabir and Isaac Dripps and Amynah Pradhan and Peter Goadsby and Philip Holland",
year = "2020",
month = may,
day = "3",
language = "English",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Differential medication overuse risk of novel anti-migraine therapeutics

AU - Saengjaroentham, Chonlawan

AU - Strother, Lauren

AU - Sultan-Jabir, Mohammad

AU - Dripps, Isaac

AU - Pradhan, Amynah

AU - Goadsby, Peter

AU - Holland, Philip

PY - 2020/5/3

Y1 - 2020/5/3

N2 - Medication overuse headache is estimated to affect two percent of the population, and is ranked in the top 20 most disabling disorders, due to its high level of disability. Several therapies used in the treatment of acute migraine are thought to be associated with medication overuse headache, including opioids and triptans. With limited treatment options, it is critical to determine the risk profile of novel therapies prior to their widespread use. The current study explores the potential medication overuse risk of two novel therapeutic drug classes, namely the ditans: 5-HT1F receptor agonists, and the gepants: calcitonin gene-related peptide receptor antagonists, in a preclinical model of medication overuse. Persistent exposure of mice to the 5-HT1F agonist LY344864, but not olcegepant produced a significant reduction in hindpaw and orofacial mechanical withdrawal thresholds as a surrogate readout of allodynia. In agreement, only LY344864 induced neuroplastic changes in trigeminal sensory afferents, increasing calcitonin gene-related peptide expression and basal trigeminal nociception. Our data highlight a differential medication overuse headache risk profile for the ditan and gepant classes of drugs that has important implications for their clinical use and patient education to help reduce the burden of medication overuse headache.

AB - Medication overuse headache is estimated to affect two percent of the population, and is ranked in the top 20 most disabling disorders, due to its high level of disability. Several therapies used in the treatment of acute migraine are thought to be associated with medication overuse headache, including opioids and triptans. With limited treatment options, it is critical to determine the risk profile of novel therapies prior to their widespread use. The current study explores the potential medication overuse risk of two novel therapeutic drug classes, namely the ditans: 5-HT1F receptor agonists, and the gepants: calcitonin gene-related peptide receptor antagonists, in a preclinical model of medication overuse. Persistent exposure of mice to the 5-HT1F agonist LY344864, but not olcegepant produced a significant reduction in hindpaw and orofacial mechanical withdrawal thresholds as a surrogate readout of allodynia. In agreement, only LY344864 induced neuroplastic changes in trigeminal sensory afferents, increasing calcitonin gene-related peptide expression and basal trigeminal nociception. Our data highlight a differential medication overuse headache risk profile for the ditan and gepant classes of drugs that has important implications for their clinical use and patient education to help reduce the burden of medication overuse headache.

KW - Migraine

KW - Headache

KW - Trigeminal ganglion

KW - Trigeminal Nerve

M3 - Article

JO - Brain

JF - Brain

SN - 0006-8950

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454